Background Polyarthritis (PA) is defined by inflammation of ≥5 joints differentiating it from oligoarthritis (OA) which affects 2-4 joints. There are limited data on the demographic and disease characteristics of psoriasis patients with either OA or PA.
Objectives Our analyses examined and characterized the baseline attributes of psoriasis subjects with PA and OA in the PREPARE trial.
Methods PREPARE was a multicenter non-interventional study conducted to estimate PsA prevalence in patients with psoriasis. Diagnosis of PA and OA was based on clinical examination by rheumatologists. Demographic and disease characteristics were assessed among patients with PA or OA at baseline.
Results A total of 406 subjects were included in these analyses; of these 222 (54.7%) had PsA following rheumatologist assessment (based on physical examination, medical history and laboratory analysis). At baseline, 253 patients had PA and 153 had OA. A significantly greater proportion of patients with PA (161/252; 63.9%) had PsA than those with OA (61/152; 40.1%) (P<0.001). Among patients with PsA, CASPAR scores were significantly higher among the PA group than the OA group (P=0.0128); 54.6% of PA patients had a CASPAR score ≥4 compared with 41.0% of AO patients. Extent of skin disease was similar for PA vs OA patients (BSA: 9.9% vs 8.9%; NAPSI: 2.2 vs 2.0; PASI: 7.0 vs 6.7). Patients with PA had significantly higher DAS28 and HAD Anxiety and Depression Scores and a significantly lower EQ-5D score than those with OA (Table 1). Percent of activity impaired and work time missed was also significantly higher in the PA group than the OA group.
Conclusions Psoriasis patients with OA and PA exhibit different phenotypes. Patients with PA had a significantly higher burden of disease and work impairment than those with OA as demonstrated by the baseline outcome data presented here. Similar levels of skin disease were observed for psoriasis patients with PA and OA.
Acknowledgements The PREPARE study (ClinTrials.gov NCT01147874) was sponsored by Pfizer Inc. Medical writing support was provided by John Bilbruck of Engage Scientific and was funded by Pfizer Inc.
Disclosure of Interest P. Helliwell Grant/research support: Pfizer, Abbie, Consultant for: Abbvie, Celgene, Pfizer, Novartis, Janssen, UCB, BMS, Eli-Lilly and Merck, H. Jones Employee of: Pfizer, A. Szumski Employee of: Pfizer, L. Marshall Employee of: Pfizer